

Commercial/Healthcare Exchange PA Criteria

Effective: July 8, 2020

Prior Authorization: Tabrecta

Products Affected: Tabrecta (capmatinib) oral tablets

Medication Description:

Tabrecta (capmatinib) is a kinase inhibitor that targets MET, including the mutant variant produced by exon 14 skipping. MET exon 14 skipping results in a protein with a missing regulatory domain that reduces its negative regulation leading to increased downstream MET signaling. Capmatinib inhibited cancer cell growth driven by a mutant MET variant lacking exon 14 at clinically achievable concentrations and demonstrated anti-tumor activity in murine tumor xenograft models derived from human lung tumors with either a mutation leading to MET exon 14 skipping or MET amplification. Capmatinib inhibited the phosphorylation of MET triggered by binding of hepatocyte growth factor or by MET amplification, as well as MET-mediated phosphorylation of downstream signaling proteins and proliferation and survival of MET-dependent cancer cells.

Covered Uses: Treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis
2. Mesenchymal-epithelial transition (MET) exon 14 skipping-status as detected by an FDA-approved test.

Age Restrictions: 18 years of age and older

Prescriber Restrictions: Prescribed by, or in consultation with, an oncologist.

Coverage Duration: 3 years

Other Criteria:

Non-Small Cell Lung Cancer (NSCLC)

- A. Patient has a diagnosis of metastatic non-small cell lung cancer (NSCLC); AND
- B. Patient's tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

References:

1. Tabrecta™ tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2020.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	06/15/2020